Publications
| Title | Abstract | Year Filter | PMID(sorted ascending) Filter |
|---|
| ebola treatments caught in limbo. | 2014 | 25079536 | |
| transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus. | ebola virus (ebov) infection in humans and non-human primates (nhps) is highly lethal, and there is limited understanding of the mechanisms associated with pathogenesis and survival. here, we describe a transcriptomic analysis of nhps that survived lethal ebov infection, compared to nhps that did not survive. it has been previously demonstrated that anticoagulant therapeutics increase the survival rate in ebov-infected nhps, and that the characteristic transcriptional profile of immune response ... | 2014 | 25079789 |
| [chikungunya fever - a new global threat]. | the recent onset of epidemics caused by viruses such as ebola, marburg, nipah, lassa, coronavirus, west-nile encephalitis, saint louis encephalitis, human immunodeficiency virus, dengue, yellow fever and venezuelan hemorrhagic fever alerts about the risk these agents represent for the global health. chikungunya virus represents a new threat. surged from remote african regions, this virus has become endemic in the indic ocean basin, the indian subcontinent and the southeast of asia, causing serio ... | 2015 | 25087211 |
| courage is treating patients with ebola. | 2014 | 25092659 | |
| canadians leading anti-ebola research. | 2014 | 25096658 | |
| largest-ever ebola outbreak still simmering in west africa. | 2014 | 25096676 | |
| ebola: an opportunity for a clinical trial? | 2014 | 25098954 | |
| integrated assessment of predicted mhc binding and cross-conservation with self reveals patterns of viral camouflage. | immune recognition of foreign proteins by t cells hinges on the formation of a ternary complex sandwiching a constituent peptide of the protein between a major histocompatibility complex (mhc) molecule and a t cell receptor (tcr). viruses have evolved means of "camouflaging" themselves, avoiding immune recognition by reducing the mhc and/or tcr binding of their constituent peptides. computer-driven t cell epitope mapping tools have been used to evaluate the degree to which particular viruses hav ... | 2014 | 25104221 |
| ebola virus disease in west africa-update. | 2014 | 25105183 | |
| ebola outbreak is a public health emergency of international concern, who warns. | 2014 | 25106874 | |
| ebola: protection of health workers on the front line. | 2014 | 25110265 | |
| serotherapy for ebola: back to the future. | 2014 | 25110967 | |
| the ebola epidemic: a global health emergency. | 2014 | 25111044 | |
| ebola and other viral haemorrhagic fevers. | 2014 | 25113010 | |
| fda allows second experimental drug to be tested in ebola patients. | 2014 | 25113141 | |
| who and partners launch ebola response plan. | 2014 | 25115001 | |
| ebola death toll rises in africa with at least 14 nurses among the dead. | at least 14 nurses are among 80 healthcare workers who have died from an outbreak of the ebola virus spreading across west africa, declared an international public health emergency last week by the world health organization (who). | 2014 | 25116521 |
| [characterization of marburg virus morphology]. | ebola virus (ebov) and marburg virus (marv) belong to the family filoviridae. filoviruses cause severe filovirus hemorrhagic fever (fhf) in humans, with high case fatality rates, and represent potential agents for bioterrorism and biological weapons. it is necessary to keep surveillance of filoviruses, even though there is no report of their isolation and patients in china so far. to characterize marv morphology, the lake victoria marburgvirus--leiden was stained negatively and observed under a ... | 2014 | 25118385 |
| ebola--underscoring the global disparities in health care resources. | 2014 | 25119491 | |
| need of surveillance response systems to combat ebola outbreaks and other emerging infectious diseases in african countries. | there is growing concern in sub-saharan africa about the spread of the ebola virus disease (evd), formerly known as ebola haemorrhagic fever, and the public health burden that it ensues. since 1976, there have been 885,343 suspected and laboratory confirmed cases of evd and the disease has claimed 2,512 cases and 932 fatality in west africa. there are certain requirements that must be met when responding to evd outbreaks and this process could incur certain challenges. for the purposes of this p ... | 2014 | 25120913 |
| how a virus blocks a cellular emergency access lane to the nucleus, stat! | early in viral infection, the stat1 transcription factor is rapidly transported into the nucleus using a nonconventional import mechanism to establish an antiviral state. in this issue, xu et al. (2014) show how the ebola virus vp24 protein precisely blocks specialized stat1 import while leaving other cellular import processes intact. | 2014 | 25121743 |
| ebola virus vp24 targets a unique nls binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated stat1. | during antiviral defense, interferon (ifn) signaling triggers nuclear transport of tyrosine-phosphorylated stat1 (py-stat1), which occurs via a subset of karyopherin alpha (kpna) nuclear transporters. many viruses, including ebola virus, actively antagonize stat1 signaling to counteract the antiviral effects of ifn. ebola virus vp24 protein (evp24) binds kpna to inhibit py-stat1 nuclear transport and render cells refractory to ifns. we describe the structure of human kpna5 c terminus in complex ... | 2014 | 25121748 |
| who gives go ahead for experimental treatments to be used in ebola outbreak. | 2014 | 25122051 | |
| infectious diseases. debate erupts on 'repurposed' drugs for ebola. | 2014 | 25124404 | |
| characterisation of novel micrornas in the black flying fox (pteropus alecto) by deep sequencing. | bats are a major source of new and emerging viral diseases. despite the fact that bats carry and shed highly pathogenic viruses including ebola, nipah and sars, they rarely display clinical symptoms of infection. host factors influencing viral replication are poorly understood in bats and are likely to include both pre- and post-transcriptional regulatory mechanisms. micrornas are a major mechanism of post-transcriptional gene regulation, however very little is known about them in bats. | 2014 | 25128405 |
| uncovering zoonoses awareness in an emerging disease 'hotspot'. | emerging infectious diseases from animals pose significant and increasing threats to human health; places of risk are simultaneously viewed as conservation and emerging disease 'hotspots'. the one world/one health paradigm is an 'assemblage' discipline. extensive research from the natural and social sciences, as well as public health have contributed to designing surveillance and response policy within the one world/one health framework. however, little research has been undertaken that consider ... | 2014 | 25128439 |
| mass gathering medicine: 2014 hajj and umra preparation as a leading example. | the importation of infectious diseases during a mass gathering may result in outbreaks. infectious diseases associated with mass gatherings vary depending on the type and location of the mass gathering. the annual hajj to makkah in saudi arabia is one of the largest annual religious mass gatherings in the world. preparation for the hajj encompasses multiple sectors to develop comprehensive plans. these plans include risk assessment, utilizing existing medical infrastructure, developing electroni ... | 2014 | 25128639 |
| a descriptive overview of the burden, distribution and characteristics of epidemics in uganda. | although uganda is a high burden country for epidemics of infectious diseases, the pattern of epidemics has not yet been adequately documented. the purpose of this study was to describe the distribution, magnitude and characteristics of recent epidemics in uganda, as a basis for informing policy on priorities for targeted prevention of epidemics. | 2013 | 25130019 |
| ebola in west africa. | 2014 | 25131986 | |
| what do we really fear? the epidemiological characteristics of ebola and our preparedness. | ebola virus disease (hereafter ebola) has a high fatality rate; currently lacks a treatment or vaccine with proven safety and efficacy, and thus many people fear this infection. as of august 13, 2014, 2,127 patients across four west african countries have been infected with the ebola virus over the past nine months. among these patients, approximately 1 in 2 has subsequently died from the disease. in response, the world health organization has declared the ebola outbreak in west africa to be a p ... | 2014 | 25132130 |
| ebola hemorrhagic fever in 2014: the tale of an evolving epidemic. | 2014 | 25133433 | |
| ebola, ethics, and public health: what next? | 2014 | 25133473 | |
| tim-family proteins inhibit hiv-1 release. | accumulating evidence indicates that t-cell immunoglobulin (ig) and mucin domain (tim) proteins play critical roles in viral infections. herein, we report that the tim-family proteins strongly inhibit hiv-1 release, resulting in diminished viral production and replication. expression of tim-1 causes hiv-1 gag and mature viral particles to accumulate on the plasma membrane. mutation of the phosphatidylserine (ps) binding sites of tim-1 abolishes its ability to block hiv-1 release. tim-1, but to a ... | 2014 | 25136083 |
| cdc: ebola risk to us patients is low, but clinicians should be on alert. | 2014 | 25138319 | |
| information resources and latest news about ebola virus disease available from ecdc. | 2014 | 25138973 | |
| ebola. | 2014 | 25139505 | |
| experimental countermeasures against ebola virus: current progress and an ethical conundrum. | 2014 | 25139506 | |
| the international ebola emergency. | 2014 | 25140855 | |
| ebola virus disease in west africa--no early end to the outbreak. | 2014 | 25140856 | |
| studying "secret serums"--toward safe, effective ebola treatments. | 2014 | 25140857 | |
| ebola 2014--new challenges, new global response and responsibility. | 2014 | 25140858 | |
| ebola virus disease: an emerging threat. | 2014 | 25140950 | |
| ebola vaccination: if not now, when? | 2014 | 25141813 | |
| ebola fever: reconciling planning with risk in u.s. hospitals. | 2014 | 25141883 | |
| analysis of the highly diverse gene borders in ebola virus reveals a distinct mechanism of transcriptional regulation. | ebola virus (ebov) belongs to the group of nonsegmented negative-sense rna viruses. the seven ebov genes are separated by variable gene borders, including short (4- or 5-nucleotide) intergenic regions (irs), a single long (144-nucleotide) ir, and gene overlaps, where the neighboring gene end and start signals share five conserved nucleotides. the unique structure of the gene overlaps and the presence of a single long ir are conserved among all filoviruses. here, we sought to determine the impact ... | 2014 | 25142600 |
| establishment and characterization of a lethal mouse model for the angola strain of marburg virus. | infections with marburg virus (marv) and ebola virus (ebov) cause severe hemorrhagic fever in humans and nonhuman primates (nhps) with fatality rates up to 90%. a number of experimental vaccine and treatment platforms have previously been shown to be protective against ebov infection. however, the rate of development for prophylactics and therapeutics against marv has been lower in comparison, possibly because a small-animal model is not widely available. here we report the development of a mous ... | 2014 | 25142608 |
| scale up the supply of experimental ebola drugs. | 2014 | 25143079 | |
| marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated sirna. | marburg virus (marv) and the closely related filovirus ebola virus cause severe and often fatal hemorrhagic fever (hf) in humans and nonhuman primates with mortality rates up to 90%. there are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against marv-angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. studies performed with other marv strains assessed candidate treatments ... | 2014 | 25143366 |
| high content image-based screening of a protease inhibitor library reveals compounds broadly active against rift valley fever virus and other highly pathogenic rna viruses. | high content image-based screening was developed as an approach to test a protease inhibitor small molecule library for antiviral activity against rift valley fever virus (rvfv) and to determine their mechanism of action. rvfv is the causative agent of severe disease of humans and animals throughout africa and the arabian peninsula. of the 849 compounds screened, 34 compounds exhibited ≥ 50% inhibition against rvfv. all of the hit compounds could be classified into 4 distinct groups based on the ... | 2014 | 25144302 |
| ebola: a failure of international collective action. | 2014 | 25150744 | |
| ethical considerations of experimental interventions in the ebola outbreak. | 2014 | 25155413 | |
| safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. | two identical single-ascending-dose studies evaluated the safety and pharmacokinetics (pk) of avi-6002 and avi-6003, two experimental combinations of phosphorodiamidate morpholino oligomers with positive charges (pmoplus) that target viral mrna encoding ebola virus and marburg virus proteins, respectively. both avi-6002 and avi-6003 were found to suppress disease in virus-infected nonhuman primates in previous studies. avi-6002 (a combination of avi-7537 and avi-7539) or avi-6003 (a combination ... | 2014 | 25155593 |
| protecting health care workers from ebola: personal protective equipment is critical but is not enough. | 2014 | 25155746 | |
| the enantiomers of the 1',6'-isomer of neplanocin a: synthesis and antiviral properties. | both enantiomers of 1',6'-isoneplanocin have been prepared from a common substituted cyclopentane epoxide in 7 steps. both compounds were subjected to dna and rna viral assessments with moderate to high activity found for both towards human cytomegalovirus, measles, ebola, norovirus, and dengue. the d-like congener also showed vaccinia and hbv effectiveness. in many of the other antiviral assays both compounds showed cytotoxicity making, in some cases, an ec50 determination not possible. the s-a ... | 2014 | 25155914 |
| experimental ebola drugs enter the limelight. | 2014 | 25157386 | |
| elucidation of the ebola virus vp24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function. | viral pathogenesis in the infected cell is a balance between antiviral responses and subversion of host-cell processes. many viral proteins specifically interact with host-cell proteins to promote virus biology. understanding these interactions can lead to knowledge gains about infection and provide potential targets for antiviral therapy. one such virus is ebola, which has profound consequences for human health and causes viral hemorrhagic fever where case fatality rates can approach 90%. the e ... | 2014 | 25158218 |
| conformational plasticity of the ebola virus matrix protein. | filoviruses are the causative agents of a severe and often fatal hemorrhagic fever with repeated outbreaks in africa. they are negative sense single stranded enveloped viruses that can cross species barriers from its natural host bats to primates including humans. the small size of the genome poses limits to viral adaption, which may be partially overcome by conformational plasticity. here we review the different conformational states of the ebola virus (ebov) matrix protein vp40 that range from ... | 2014 | 25159197 |
| a practical treatment for patients with ebola virus disease. | 2015 | 25160984 | |
| largest-ever outbreak of ebola virus disease thrusts experimental therapies, vaccines into spotlight. | 2014 | 25162140 | |
| face to face with ebola--an emergency care center in sierra leone. | 2014 | 25162580 | |
| four in 10 us people fear large outbreak of ebola. | 2014 | 25163929 | |
| world struggles to stop ebola. | 2014 | 25164728 | |
| caring for critically ill patients with ebola virus disease. perspectives from west africa. | the largest ever ebola virus disease outbreak is ravaging west africa. the constellation of little public health infrastructure, low levels of health literacy, limited acute care and infection prevention and control resources, densely populated areas, and a highly transmissible and lethal viral infection have led to thousands of confirmed, probable, or suspected cases thus far. ebola virus disease is characterized by a febrile severe illness with profound gastrointestinal manifestations and is c ... | 2014 | 25166884 |
| reverse genetics systems as tools for the development of novel therapies against filoviruses. | filoviruses cause severe hemorrhagic fevers with case fatality rates of up to 90%, for which no antivirals are currently available. their categorization as biosafety level 4 agents restricts work with infectious viruses to a few maximum containment laboratories worldwide, which constitutes a significant obstacle for the development of countermeasures. reverse genetics facilitates the generation of recombinant filoviruses, including reporter-expressing viruses, which have been increasingly used f ... | 2014 | 25169588 |
| micrornas in kidney transplantation. | the discovery of novel classes of non-coding rnas (ncrnas) has revolutionized medicine. long thought to be a mere cellular housekeeper, surprising functions have recently been uncovered. micrornas (mirnas), are a representative of the class of short ncrnas, play a fundamental role in the control of dna and protein biosynthesis and activity as well as pathology. currently, mirnas are being investigated as diagnostic and prognostic markers and potential therapeutic targets in kidney transplantatio ... | 2015 | 25170095 |
| infectious disease. genomes reveal start of ebola outbreak. | 2014 | 25170128 | |
| reversion of advanced ebola virus disease in nonhuman primates with zmapp. | without an approved vaccine or treatments, ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. these approaches, however, have yet to end the 2014 outbreak of ebola after its prolonged presence in west africa. here we show that a combination of monoclonal antibodies (zmapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. high fever, viraemia a ... | 2014 | 25171469 |
| medical research: ebola therapy protects severely ill monkeys. | 2014 | 25171470 | |
| immunization with vesicular stomatitis virus vaccine expressing the ebola glycoprotein provides sustained long-term protection in rodents. | ebola virus (ebov) infections cause lethal hemorrhagic fever in humans, resulting in up to 90% mortality. ebov outbreaks are sporadic and unpredictable in nature; therefore, a vaccine that is able to provide durable immunity is needed to protect those who are at risk of exposure to the virus. this study assesses the long-term efficacy of the vesicular stomatitis virus (vsv)-based vaccine (vsvδg/ebovgp) in two rodent models of ebov infection. mice and guinea pigs were first immunized with 2×10(4) ... | 2014 | 25173474 |
| is respiratory protection appropriate in the ebola response? | 2014 | 25178253 | |
| forty years of the war against ebola. | humans have been fighting against the ebola virus disease (evd) since its first outbreak in 1976 in southern sudan and yambuku in zaire which lies on the ebola river. according to the data from the world health organization (who, 2014b), the first outbreak claimed 431 lives in 1976, and the disease awoke transiently in sudan three years later and then disappeared for 15 years afterwards. following that, large outbreaks appeared in 1995 in zaire with 250 deaths of people, 2001-2002 in uganda with ... | 2014 | 25183030 |
| does this patient have ebola virus disease? | 2014 | 25183574 | |
| ebola epidemic outpacing response: msf. | 2014 | 25183725 | |
| laboratory test support for ebola patients within a high-containment facility. | 2014 | 25184220 | |
| a good death---ebola and sacrifice. | 2014 | 25184515 | |
| healthcare staff advised to prepare for ebola cases in uk. | emergency nurses are accustomed to responding to any kind of presentation, and so should not be alarmed by the latest national guidance on identifying and caring for patients with the ebola virus. | 2014 | 25185907 |
| ebola drug trials set to begin amid crisis. | 2014 | 25186878 | |
| us signs contract with zmapp maker to accelerate development of the ebola drug. | 2014 | 25189475 | |
| ebola virus disease: general characteristics, thoughts, and perspectives. | 2014 | 25189614 | |
| infectious disease. estimating the ebola epidemic. | 2014 | 25190771 | |
| world leaders are ignoring worldwide threat of ebola, says msf. | 2014 | 25192726 | |
| case fatality rates of ebola virus diseases: a meta-analysis of world health organization data. | our objective was to estimate the case fatality rates of zaire, sudan, and bundibugyo ebola species, responsible for sometimes-lethal hemorrhagic fevers. | 2014 | 25193630 |
| more health staff are needed to contain ebola outbreak, warns who. | 2014 | 25193934 | |
| taking a religious perspective to contain ebola. | 2014 | 25194448 | |
| [infectiological emergency of worldwide significance. ebola out of control? (interview by dr.robert bublak)]. | 2014 | 25195378 | |
| stakeholder prioritization of zoonoses in japan with analytic hierarchy process method. | there exists an urgent need to develop iterative risk assessment strategies of zoonotic diseases. the aim of this study is to develop a method of prioritizing 98 zoonoses derived from animal pathogens in japan and to involve four major groups of stakeholders: researchers, physicians, public health officials, and citizens. we used a combination of risk profiling and analytic hierarchy process (ahp). profiling risk was accomplished with semi-quantitative analysis of existing public health data. ah ... | 2015 | 25195643 |
| a tribute to sheik humarr khan and all the healthcare workers in west africa who have sacrificed in the fight against ebola virus disease: mae we hush. | the kenema government hospital lassa fever ward in sierra leone, directed since 2005 by dr. sheikh humarr khan, is the only medical unit in the world devoted exclusively to patient care and research of a viral hemorrhagic fever. when ebola virus disease unexpectedly appeared in west africa in late 2013 and eventually spread to kenema, khan and his fellow healthcare workers remained at their posts, providing care to patients with this devastating illness. khan and the chief nurse, mbalu fonnie, b ... | 2014 | 25196533 |
| ebola: a call to action. | the size, speed and potential reach of the 2014 ebola virus outbreak in west africa presents a wake-up call to the research and pharmaceutical communities - and to federal governments - of the continuing need to invest resources in the study and cure of emerging infectious diseases. | 2014 | 25198036 |
| what, ebola here? | 2014 | 25198438 | |
| first ebola treatment is approved by who. | 2014 | 25200068 | |
| who enters new terrain in ebola research. | 2014 | 25200757 | |
| ebola: towards an international health systems fund. | 2014 | 25201591 | |
| mapping the zoonotic niche of ebola virus disease in africa. | ebola virus disease (evd) is a complex zoonosis that is highly virulent in humans. the largest recorded outbreak of evd is ongoing in west africa, outside of its previously reported and predicted niche. we assembled location data on all recorded zoonotic transmission to humans and ebola virus infection in bats and primates (1976-2014). using species distribution models, these occurrence data were paired with environmental covariates to predict a zoonotic transmission niche covering 22 countries ... | 2014 | 25201877 |
| biotech drugs too little, too late for ebola outbreak. | 2014 | 25203010 | |
| what obstetrician-gynecologists should know about ebola: a perspective from the centers for disease control and prevention. | west africa is currently in the midst of the largest ebola outbreak in history. although there have been no ebola virus disease cases identified in the united states, two u.s. health care workers with ebola virus disease were medically evacuated from liberia to the united states in early august 2014. the centers for disease control and prevention has been working closely with other u.s. government agencies and international and nongovernmental partners for several months to respond to this globa ... | 2014 | 25203368 |
| understanding the ebola threat: the uk government's response. | 2016 | 25203758 | |
| ebola in west africa: the outbreak able to change many things. | 2014 | 25204860 | |
| the ebola outbreak in western africa: ethical obligations for care. | the recent wave of the ebola virus disease (evd) in western africa and efforts to control the disease where the health system requires strengthening raises a number of ethical challenges for healthcare workers practicing in these countries. we discuss the implications of weak health systems for controlling evd and limitations of the ethical obligation to provide care for patients with evd using nigeria as a case study. we highlight the right of healthcare workers to protection that should be obl ... | 2016 | 25205389 |
| nhs contribution to the ebola epidemic. | 2014 | 25205392 | |
| ebola: is there a hope from treatment with cardiovascular drugs? | 2014 | 25205490 |